High margin foundation
with an undervalued R&D pipeline

Camurus has transformed from a high-burn biotech into a profitable specialty pharmaceutical company, supported by the strong cash-generating Buvidal/Brixadi franchise and its proprietary FluidCrystal drug delivery platform. With a debt-free balance sheet, growing royalty revenues, and several late-stage pipeline catalysts approaching, including Oclaiz and the SORENTO phase 3 study, the company is entering a potentially transformative period of value creation.

Analyst: Noah Palosari

05/04/2026